Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development

Kricker, Jennifer A.; Page, Clive; Gardarsson, Fridrik Runar; Baldursson, Ólafur; Guðjónsson, Þórarinn; Parnham, Michael J.

doi:10.1124/pharmrev.121.000300

Cited by 51 publications

(53 citation statements)

References 465 publications

(440 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, due to the pandemic of COVID-19, the rate of MRMP seems to have decreased in accordance with the decreasing number of cases of MP infections. Whereas antibiotics are possibly used to prevent pneumonia with bacterial superimposition, macrolide might be also used as nonantimicrobial actions [ 54 ]. However, the method of diagnosis has improved, enabling the immediate diagnosis and prescription of appropriate antibiotics for MRMP.…”

Section: Discussionmentioning

confidence: 99%

Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-Resistant Mycoplasma pneumoniae

Oishi

Ouchi

2022

JCM

View full text Add to dashboard Cite

Among Mycoplasma pneumoniae (MP) is one of the major pathogens causing lower respiratory tract infection. Macrolide-resistant Mycoplasma pneumoniae (MRMP) isolates have been increasing and has become a global concern, especially in East Asian countries. This affects the treatment of MP infection; that is, some patients with MRMP infections fever cannot be controlled despite macrolide therapy. Therefore, alternative therapies, including secondary antimicrobials, including tetracyclines, fluoroquinolones, or systemic corticosteroids, were introduced. However, there are insufficient data on these alternative therapies. Thus, this article provides reviews of the recent trends in the epidemiology, diagnosis, and treatment of MRMP.

show abstract

Section: Discussionmentioning

confidence: 99%

Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-Resistant Mycoplasma pneumoniae

Oishi

Ouchi

2022

JCM

View full text Add to dashboard Cite

show abstract

“…No efficacy was shown independently of the distinct employed formulations analyzed in the subgroups of the present research (azithromycin, amoxicillin plus metronidazole, and amoxicillin). Azithromycin (Zithromax) is a macrolide antibiotic, and is a widely prescribed broad-spectrum antibacterial, particularly for respiratory infections [ 62 ]. Azithromycin is detectable in inflamed periodontal tissues beyond 14 days after systemic administration and is associated with clinical and microbiological improvement [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review and Meta-Analysis of Systemic Antibiotic Therapy in the Treatment of Peri-Implantitis

Toledano-Osorio

Vallecillo

Toledano³

et al. 2022

IJERPH

View full text Add to dashboard Cite

Research has been conducted into the advantages of the systemic administration of antibiotics. The aim of this systematic review and meta-analysis was to assess the efficacy of systemic antibiotic administration in the treatment of peri-implantitis in terms of bleeding on probing (BoP) and probing pocket depth (PPD). Literature searches were performed across PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) to identify randomized controlled trials and observational clinical studies. After peri-implantitis treatment, PPD was reduced by 0.1 mm (p = 0.58; IC 95% [−0.24, 0.47]), indicating a non-significant effect of antibiotic administration on PPD. The BoP odds ratio value was 1.15 (p = 0.5; IC 95% [0.75, 1.75]), indicating that the likelihood of bleeding is almost similar between the test and control groups. Secondary outcomes were found, such as reduced clinical attachment level, lower suppuration and recession, less bone loss, and a reduction in total bacterial counts. In the treatment of peri-implantitis, the systemic antibiotic application reduces neither PPD nor BoP. Therefore, the systemic administration of antibiotics, in the case of peri-implantitis, should be rethought in light of the present results, contributing to address the problem of increasing antibiotic resistance.

show abstract

“…Способность макролидов подавлять секрецию слизи секреторными клетками в дыхательных путях была впервые показана в исследованиях для эритромицина и впоследствии подтверждена в условиях in vitro и in vivo и для других макролидов [10,51]. Влияние макролидов на секрецию слизи частично опосредовано ингибированием вызванной цитокинами индукции экспрессии гена MUC5AC, кодирующего белок муцин 5AC, который представляет собой гелеобразный муциновый продукт бокаловидных клеток.…”

Section: подавление секреции слизиunclassified

“…Аномальная секреция слизи является неотъемлемым звеном патогенеза ряда распространенных заболеваний легких, таких как бронхиальная астма и ХОБЛ [55,56]. Кроме того, аномальная секреция слизи является важным компонентом при развитии муковисцидоза [51]. Поскольку гиперсекреция слизи сопряжена с худшими исходами при бронхиальной астме и ХОБЛ, применение макролидов при указанных заболеваниях может оказаться эффективным благодаря снижению продукции слизи [57].…”

Section: подавление секреции слизиunclassified

“…Эпителиальный барьер, присутствующий в таких органах, как кожа, дыхательная, мочеполовая и желудочно-кишечная системы, позволяет организму противостоять внешним угрозам со стороны инфекционных агентов и токсичных химических веществ. Укрепляя целостность эпителиального барьера, можно препятствовать инвазии экзогенных агентов и повреждениям вследствие их воздействия [51]. Параклеточная проницаемость в значительной степени зависит от межклеточных соединений, особенно плотных контактов, которые представляют собой белковые комплексы, соединяющие соседние эпителиальные клетки и образованные более чем 40 видами различных белков (включая трансмембранные белки: клаудины, окклюдин, молекулы соединительной адгезии и трицеллюлин; а также белки периферических мембран) [59].…”

Section: усиление барьерных свойств эпителияunclassified

See 1 more Smart Citation

Non-antimicrobial effects of macrolides: literature review

Skryabina¹,

Nikiforov²,

Shakhmardanov³

et al. 2021

Immunopathol Allergol Infectol

View full text Add to dashboard Cite

The aim of this work is to review current publications on the non-antibacterial effects of macrolides. Macrolides are among the most widely prescribed broad-spectrum antibacterial drugs, especially in patients with respiratory infections. It is now recognized that drugs of this group, in particular azithromycin, also have an immunomodulatory effect, which leads to their therapeutic effect not only in infectious but in other chronic inflammatory diseases also. However, the frequent and prolonged use of macrolides in the treatment of respiratory tract diseases, and recently azithromycin in the treatment of COVID-19, has led to an increase in bacterial resistance to antibiotics of this group. Results: it was shown that one of the key aspects of the development of chronic inflammation of the respiratory tract (for instance, chronic obstructive pulmonary disease) is the loss of the protective epithelial barrier due to the effects of pathogens and pollutants. Azithromycin has been shown to enhance the barrier properties of airway epithelial cells over time, which makes an important contribution to its therapeutic effectiveness. The main non-antibacterial effects of macrolides are considered, which in the future can be applied in treatment of inflammatory diseases associated with airway epithelium damage.

show abstract

Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development

Cited by 51 publications

References 465 publications

Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-Resistant Mycoplasma pneumoniae

Recent Trends in the Epidemiology, Diagnosis, and Treatment of Macrolide-Resistant Mycoplasma pneumoniae

A Systematic Review and Meta-Analysis of Systemic Antibiotic Therapy in the Treatment of Peri-Implantitis

Non-antimicrobial effects of macrolides: literature review

Contact Info

Product

Resources

About